APRINOIA Therapeutics

About APRINOIA Therapeutics

APRINOIA Therapeutics is dedicated to offering hope to patients with neurodegenerative diseases by providing next-generation diagnostic tools and targeted therapeutics to protect brain health and preserve dignity.

Products & Services

Diagnostic Programs:Active programs aimed at improving early-stage diagnosis of neurodegenerative diseases and tracking disease progression in response to therapies.

Therapeutics Pipeline:A robust pipeline of small and large molecules targeting proteins and pathways related to neurodegenerative disorders like Alzheimer's and Parkinson's, with the goal of slowing disease progression.

Specialties

Precision Medicine in Neuroscience Targeting Protein Aggregates (tau, α-synuclein) Neurodegenerative Disease Diagnostics and Therapeutics Alzheimer's and Parkinson's Disease Research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Strategic Investment T: - FT: Strategic Investment	A: 4400000 MR: - FA: approximately $4.4M FAN: 4400000	D: 2023-09-11 FD: 2023-09-11	1 investors

Strategic Investment Latest

2023-09-11

$4.4M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Ming-Kuei Jang

Founder, Chairman, and Chief Executive Officer

M

Masaomi Miyamoto

Executive Vice President of R&D and Operations

L

Lili Zhang

Senior Vice President, Head of Preclinical Development

H

Hsiou-Chi Liou, Ph.D., CFA

Head, Corporate Development and Strategy

C

Chin-Yin Tai

Vice President of Neurobiology

S

Steven Paget

Principal Scientist

View 3 more team members with Pro

Unlock Full Team Directory

Recent News